Studying Safety & Efficacy of Axiostat® Dressing in Acute Hemorrhage Due to Trauma-Comparative Study
|ClinicalTrials.gov Identifier: NCT03035695|
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : January 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Bleeding||Device: Axiostat® Device: Cotton Gauze||Not Applicable|
Accidents and trauma comprise leading causes of death and disability throughout the world. In developing countries such as India, where emergency trauma care is still in its infancy, it accounts for almost 10% deaths every year. Lack of adequate pre-hospital care and uncontrolled bleeding from wound site are stated to be the prominent reasons for such deaths.
In this study, a novel chitosan-based haemostatic dressing (Axiostat®, Axio Biosolutions, India) was investigated as an initial hemorrhage controlling device in pre-hospital scenario. The study was conducted with the help of 35 Emergency Medical Technicians (EMTs).
A total of 133 patients with scalp wound injury were identified for the study, of which 104 patients meeting the selection criteria were included in the study. The selected patients were randomly assigned into two groups, the test group consisting of 47 subjects received Axiostat® treatment; whereas, 57 subjects in the control group were treated with a conventional cotton-gauze dressing. All subjects needed suturing as the subjects included in the study were brought with open scalp wounds.
The Axiostat® showed a superior efficacy in controlling bleeding in comparison to the cotton gauze. The average time for haemostasis with cotton gauze dressing was about 18.56 ± 5.04 minutes; while with Axiostat® haemostasis was achieved in less than 5 minutes (4.68 ± 1.04 min).
On analyzing this study, it was evident that Axiostat® dressing enables early haemostasis which prevents much blood loss and the wound becomes very clean on removal of dressing for later wound suturing when compared to normal cotton gauze.
These findings demonstrated the potential of Axiostat® as a first-line intervention in controlling acute hemorrhage in the pre-hospital scenarios.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||104 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pre Hospital Hemorrhagic Control Effectiveness of Axiostat® Dressing Versus Conventional Method in Acute Hemorrhage Due to Trauma|
|Actual Study Start Date :||May 2012|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Experimental: Axiostat® Size
Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.
Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area.
Other Name: Haemostatic dressing
Active Comparator: Cotton Gauze
Cotton Gauze Size: 8 x 5 cm
Device: Cotton Gauze
- Time to achieve hemostasis [ Time Frame: 1 Day ]Time to achieve hemostasis by observing the time at which blood oozing through or from periphery of the dressing stops.
- Number of patients with rebleeding [ Time Frame: 1 Day ]Number of patients with rebleeding will be counted (unit of measurement is number/count of patients)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03035695
|Malabar Insitute of Medical Sciences|
|Calicut, Kerela, India, 673016|
|Principal Investigator:||Dr. Mohmmad Kabeer||Malabar Institute of Medical Sciences|